Rituximab-Induced Interstitial Lung Disease: A Possible Underestimated Complication-A Systematic Review.

ABSTRACT: Background: Rituximab, a monoclonal antibody targeting CD20, has revolutionized the management of B-cell lymphoproliferative disorders and some immune conditions, significantly improving disease control and patient survival. Beyond its indisputable therapeutic benefits, rituximab can cause serious pulmonary adverse events, particularly interstitial lung disease (R-ILD). Diagnosing R-ILD is challenging due to nonspecific clinical and imagistic features, and its true incidence is possibly underestimated. Methods: We conducted a systematic review to synthesize current evidence on R-ILD, focusing on its incidence, diagnostic approaches, management strategies and clinical outcomes. A comprehensive search of PubMed/MEDLINE was performed using the term "rituximab induced interstitia

SUBMITTER: Zamfir AS 

PROVIDER: S-EPMC12691211 | biostudies-literature | 2025 Nov

REPOSITORIES: biostudies-literature